Xiac

Quick links to important sections

Xiac

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xiac

Quick Facts

Property Description
Active Ingredient Ceftriaxone (as sodium salt)
Form Powder for solution for injection or infusion
Pharmacological Class Third-Generation Cephalosporin Antibiotic
General Purpose To eliminate susceptible bacterial infections
Origin Semisynthetic

What Type of Antibiotic is Xiac?

Xiac is classified as a third-generation cephalosporin antibiotic, a semisynthetic compound belonging to the larger family of beta-lactam antibiotics. The active ingredient, ceftriaxone, is positioned in this advanced class due to its chemical structure, which is clinically recognized for granting it enhanced stability and effectiveness compared to earlier cephalosporins. This classification is vital because it establishes the drug as a powerful agent with a broad spectrum of activity against numerous Gram-negative and Gram-positive bacteria. The broad spectrum of ceftriaxone makes it a valuable tool in managing diverse severe bacterial challenges.


Composition and Physical Form of Xiac (Ceftriaxone)

The medicine is primarily composed of the key anti-infective agent, ceftriaxone sodium, and is supplied as a sterile, pale-yellow powder for solution for injection or infusion in a vial. This formulation is a differentiating factor, as it requires parenteral administration and is generally reserved for hospital or specialized outpatient use. Certain combination products, such as formulations containing sulbactam, are also available. Sulbactam is a beta-lactamase inhibitor added specifically to neutralize bacterial enzymes that can degrade the ceftriaxone molecule. This strategic combination preserves the antibiotic’s full killing power against potentially resistant strains.


What is the General Purpose of Ceftriaxone?

The general purpose of ceftriaxone is to achieve the swift and definitive elimination of susceptible bacteria from the body by acting as a bactericidal agent. This action is supported by pharmacological studies confirming its efficacy against pathogens responsible for a variety of severe infections. The drug works by disrupting the synthesis of the bacterial peptidoglycan cell wall, leading directly to the death and disintegration of the pathogen. Ceftriaxone is an established agent whose principal benefit is its reliable effect in eliminating the cause of a bacterial infection. This core mechanism ensures a high-level therapeutic benefit in both adults and children, providing a decisive intervention to arrest and reverse the infectious process caused by bacterial pathogens.

What side effects are possible with Xiac?

Possible Side Effects and Safety Information

The safety profile of Xiac is organized by regulatory bodies based on the frequency and severity of reported adverse reactions from clinical trials and post-marketing surveillance.


Adverse Reactions by Frequency

The following are some of the known side effects that have been formally categorized in regulatory documents:

  • Common (may affect up to 1 in 10 people): Diarrhea, skin rash, and specific changes in laboratory blood values, including an increase in eosinophils and decreases in white blood cells or platelets.
  • Uncommon (may affect up to 1 in 100 people): Information is also documented for events that occur less frequently but are officially recognized as potential risks.

Serious and Clinically Significant Reactions

Regulatory documents highlight the potential for severe allergic reactions (hypersensitivity) to Xiac or its components. These reactions, which may involve severe rash, swelling, and difficulty breathing, require immediate medical attention and are grounds for discontinuing the medicine. Additionally, the official safety profile includes the potential for abnormalities in liver function tests and other blood-related changes.


Safety-Related Restrictions and Considerations

Contraindications: Xiac must not be used in individuals with a documented hypersensitivity or allergy to the medicine or its class of compounds.

Population Considerations:

  • Severe Organ Impairment: Caution is advised, and close monitoring may be required for individuals with severe liver disease or kidney impairment.
  • Pregnancy and Breastfeeding: Safety information advises caution, with official recommendations noting that prolonged use during pregnancy should be avoided. Discontinuation of breastfeeding may be necessary depending on the clinical scenario, as required by regulatory guidance.

Overdose and Emergency Response

Overdose and when to seek help for Xiac (Ceftriaxone)


Documented Overdose Manifestations

Overdose of ceftriaxone is officially documented to present with gastrointestinal symptoms, including nausea, vomiting, and diarrhea. Severe manifestations associated with very high plasma concentrations may affect the central nervous system, including convulsions and reversible encephalopathy. A serious, non-acute outcome linked to overexposure is the formation of ceftriaxone-calcium salt precipitates, which can manifest as pseudolithiasis in the gallbladder or renal stones.


Emergency Actions and Supportive Management

Immediate medical attention must be sought if an overdose is suspected or if severe signs such as neurological changes are observed. The regulatory guidance for managing overexposure involves providing symptomatic and supportive treatment to address the clinical effects and correct any resulting fluid and electrolyte imbalances.

Regulatory information specifies that no specific antidote is known for ceftriaxone. Furthermore, procedures like hemodialysis and peritoneal dialysis are officially stated to be not effective for enhancing the elimination of the drug from the body. Patients with impaired renal clearance are noted to be at an increased risk for severe central nervous system toxicity due to the elevated drug levels in their system.

Therapeutic Uses of Xiac

What Xiac Treats: Main Uses and Benefits

Xiac (Ceftriaxone) is an antibiotic treatment reserved for managing moderate-to-severe bacterial infections and the pronounced symptoms they cause. The primary therapeutic benefit supports the body in managing susceptible bacterial pathogens, and the medication is applied across several critical clinical domains.

This intervention is commonly used to address conditions associated with heightened physiological stress, such as bloodstream infections (sepsis), the central nervous system (meningitis), and severe infections of the lungs (pneumonia) or the urinary tract. Xiac is also applied in specialized scenarios, such as the supportive treatment of gonorrhea and as surgical prophylaxis. This approach assists with maintaining functional stability by addressing acute systemic signs of illness, including uncontrolled high fever and chills, and contributes to easing the overall symptom load.

Quick Fact: Support for Symptoms of Systemic Imbalance

Xiac is commonly used across conditions marked by increased physiological stress, providing support that helps ease the overall symptom burden related to high fever and chills.

Regulatory References

  1. NIH DailyMed official drug label

Eligibility and Restrictions for Use

Who Can and Cannot Use Xiac?

The population eligibility for Xiac (Ceftriaxone) is strictly governed by regulatory labeling, defining groups who must not use the medicine (contraindications) and those for whom use is restricted or established.

Absolute Contraindications

Patient Group
Patients with a known severe hypersensitivity or allergic reaction to ceftriaxone, any other cephalosporin antibiotic, or any other β-lactam antibacterial agents (e.g., penicillins, carbapenems).
Hyperbilirubinemic neonates and preterm neonates up to 41 weeks postmenstrual age.
Neonates (≤ 28 days) who are receiving or scheduled to receive intravenous calcium-containing solutions.

Established & Restricted Use

Use is established for adults, adolescents (≥ 12 years and ≥ 50 kg), and children (15 days to 12 years). Use is also established in older adults, where dose adjustment is typically unnecessary. Restrictions apply to patients with concurrent severe renal and hepatic dysfunction, who generally must not exceed a maximum daily dose of 2 grams. Trace amounts are documented to cross the placenta and are detected in human breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Xiac (Ceftriaxone), strictly based on governmental regulatory information.


Administration and Combination Restrictions

Category Substance or Restriction Official Classification/Outcome
Contraindicated Combination Calcium-containing IV solutions Absolutely prohibited in neonates (le 28 days old) due to the risk of ceftriaxone-calcium precipitation [NIH DailyMed].
Procedural Restriction Calcium-containing IV solutions Simultaneous co-administration via the same line is prohibited in all patients [MHRA]. Sequential administration is permitted only if the line is thoroughly flushed between infusions [FDA].
Physical Incompatibility Vancomycin, Aminoglycosides, Amsacrine, Fluconazole Must not be mixed or co-administered in the same intravenous line [FDA].

Pharmacological Interaction Outcomes

Co-administration of Xiac with anticoagulants such as Warfarin is associated with an increased risk of bleeding due to officially documented alterations in prothrombin time [FDA]. An interaction with Cyclosporine may result in increased plasma levels of the co-administered drug [Regulatory sources]. Furthermore, Chloramphenicol has demonstrated antagonistic effects with Xiac in laboratory studies, potentially reducing its effectiveness [FDA]. Co-administration with certain Local Anesthetics may carry an increased risk of methemoglobinemia in susceptible individuals [Drugs@FDA].

Mechanism of Action

Irreversible Sabotage of Bacterial Cell Wall Assembly

This domain covers the primary, bactericidal mechanism of Xiac's active ingredient, Ceftriaxone. The drug acts as an irreversible inhibitor of key bacterial enzymes called Penicillin-Binding Proteins (PBPs), which are essential for constructing the pathogen's protective outer layer, the peptidoglycan cell wall. This molecular attack prevents the crucial cross-linking of the cell wall structure, which leads directly to the loss of osmotic stability, triggering bacterial cell lysis.


️ Enzymatic Protection and Potency Maintenance

For the combination product, a critical secondary mechanism involves the component Sulbactam. This molecule acts as a 'suicide' inhibitor against bacterial beta-lactamase enzymes, which are produced by some resistant strains to destroy Ceftriaxone. By neutralizing these beta-lactamases, Sulbactam effectively protects the primary drug molecule, ensuring it can reach and inhibit the PBPs. This action results in the maintenance of Ceftriaxone's bactericidal activity against otherwise resistant pathogens.


️ Functional Constraint by Target Modification

This domain addresses the biological limitations of the mechanism, primarily where target modification is present (altered PBP structure). Bacteria can alter the structure of their Penicillin-Binding Proteins (PBPs), causing them to lose affinity for Ceftriaxone. This reduced binding weakens the inhibitory action, enabling the bacteria to maintain adequate cell wall synthesis and survive, functionally constraining the drug's intended lethal mechanism.

Dosage and Administration Information

How Xiac is Used: Official Administration Guidelines

The use of Xiac (Ceftriaxone) is governed by parenteral administration requirements and specific, official dosing protocols. The medicine is supplied as a sterile powder for solution for injection or infusion, necessitating mandatory reconstitution and dilution prior to delivery.


Administration Scope and Dosing

Feature Official Labeled Instruction
Route of Administration Intravenous (IV) injection or infusion, or Intramuscular (IM) deep injection.
Usual Adult Daily Dose Generally 1 g to 2 g, administered once daily (every 24 hours).
Maximum Daily Dose Should not exceed 4 g (grams) for severe infections.

Procedural and Population Requirements

The standard frequency pattern for Xiac is once daily, although it may be administered in divided doses twice daily (every 12 hours) in certain scenarios. Administration speed is regulated; IV bolus injection must be given slowly over 2 to 4 minutes, while intermittent IV infusion must last at least 30 minutes.

Official instructions mandate that Xiac must not be mixed with or administered simultaneously with any solutions containing calcium, to prevent the risk of precipitation. Regarding specific populations, pediatric dosing is calculated based on body weight (mg/kg). Furthermore, dosage adjustment is generally not necessary for patients with renal or hepatic impairment when the dose is leq 2 g daily, but a maximum dose of 2 g is specified for those with co-existing severe impairment. These standardized procedures define the structural framework for the drug's proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xiac

The research evidence for Xiac (Ceftriaxone) comes from clinical evaluations that was studied for conditions associated with acute or disruptive episodes. These studies follow strict scientific principles and include comparisons against other standard antibiotic treatments. The research was observed in contexts that include research exploring short-term symptom changes related to systemic or functional imbalance.


Evidence for Severe Central Nervous System and Bloodstream Infections

For severe infections affecting the central nervous system, such as Bacterial Meningitis, research primarily relies on Randomized Controlled Trials (RCTs) and systematic reviews. These studies monitored outcomes related to daily functioning or activity level and patient survival rates in cohorts of adults and pediatric patients. Findings describe patterns observed in the studies related to the time required for clearance of bacteria from the cerebrospinal fluid. In Bloodstream Infections (Sepsis/Bacteremia), research was studied for conditions involving periods of heightened symptoms, observing survival over defined time intervals and documenting the clearance of bacteria from the blood.

Evidence for Severe Lung and Urinary Tract Infections

Research has explored Xiac’s use in severe respiratory conditions like Community-Acquired Pneumonia (SCAP). The studies explored outcomes related to outcomes related to systemic or functional imbalance, and also assessed the required duration of hospitalization. For Complicated Urinary Tract Infections (cUTI), the findings contribute to understanding symptom patterns related to microbiological eradication from the urine, with outcomes related to physical discomfort being monitored.

Research Gaps and Remaining Uncertainties

Official research documentation highlights areas where further investigation is needed. For many uses, data are still emerging regarding the impact of long-term effects, and long-term effects are not fully established across all studied populations. Subgroup findings are uncertain for some specific comorbid conditions or when the infection is caused by rare pathogens. The evidence base may be influenced by emerging antibiotic resistance, meaning comparative evidence is lacking between older studies and current pathogen patterns.

Key Studies & References

  1. Ceftriaxone therapy of meningitis and serious infections
  2. Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia
  3. FDA Label: Ceftriaxone Sodium Injection, powder, for solution (DailyMed) (Regulatory Document/Indications)

Frequently Asked Questions (FAQ)

Common questions about Xiac (FAQ)

Q: How quickly should I expect Xiac to start working?

A: Xiac is a medicine that is delivered directly into the body, and its action is noted in clinical settings shortly after administration. Official product information describes its elimination half-life—the time it takes for half of the drug to be cleared from the bloodstream—as typically being in the range of 5.8 to 8.7 hours in healthy adults. This measure helps understand the drug's persistence in the body.

Q: Is it safe to drink alcohol while taking Xiac?

A: Official information does not document a specific pharmacological interaction between Xiac and alcohol that causes a severe reaction, such as a disulfiram-like effect. Regulatory documents focus strictly on the drug's chemical properties and do not provide guidance on the use of alcohol in the context of managing an active infection.

Q: Does Xiac interact with birth control pills?

A: Regulatory information indicates that certain antibiotics, including those in the same class as Xiac (ceftriaxone), have the potential to reduce the effectiveness of birth control pills that contain estradiol. Official prescribing information describes a potential for reduced effectiveness in this context.

Q: If I feel better, should I stop taking Xiac?

A: Official patient information describes that completing the entire course, as directed by a healthcare professional, is an established part of the treatment for bacterial infections. This practice is noted as being important for preventing the development of drug-resistant bacteria or the return of the infection.

Q: How long does Xiac stay in your system after you stop taking it?

A: The time it takes for half of the dose to be eliminated from the body is measured by the elimination half-life. This value is officially described for Xiac in adults as ranging from 5.8 to 8.7 hours. It generally takes several half-lives for the medicine to be fully cleared from the body.

Q: Do I need a prescription to get Xiac?

A: Yes, regulatory authorities universally classify the active ingredient in Xiac, ceftriaxone, as a prescription-only medicine. Its formulation for injection or infusion means it is typically administered in a hospital or specialized outpatient setting.

Q: What makes Xiac different from other similar drugs?

A: Xiac (ceftriaxone) is officially classified as a third-generation cephalosporin, which is structurally described as having enhanced stability and a broad spectrum of activity against bacteria. Its long elimination half-life is noted as a differentiating factor that allows for its typical once-daily administration.

Q: Is there a generic version of Xiac?

A: Yes, the active ingredient in Xiac, ceftriaxone, is well-established and available as a generic medicine in the United States and other global regions. Generic versions contain the same active ingredient and are subject to the same strict regulatory standards.

Q: What happens if I forget to take a dose of Xiac?

A: Since Xiac is typically administered through injection or infusion by a healthcare professional, regulatory patient information describes the importance of immediately contacting the prescriber if a scheduled dose is missed. This allows your medical team to determine the correct and non-directive next steps.

Q: Can Xiac be used for purposes other than its main approved uses?

A: Regulatory agencies only approve medicines for the specific uses listed in the official labeling. Use outside of these approved indications is referred to as 'off-label' use. Regulatory bodies do not provide guidance or recommendations for any off-label uses.

Q: Is it common to feel tired while taking Xiac?

A: Tiredness, fatigue, or excessive sleepiness (somnolence) are not listed as common side effects of Xiac. However, official warnings mention these symptoms as potential signs of other reactions, such as hemolytic anemia or certain neurological adverse reactions, and are noted in official warnings as requiring reporting to a healthcare provider.

Q: Can Xiac affect my sleep schedule?

A: Official documents describe that Xiac has been associated with neurological adverse reactions, which include disturbances of consciousness, such as somnolence (being very sleepy) and lethargy. The official label indicates that any unusual neurological signs should be reported.

Q: Are there any long-term side effects associated with Xiac?

A: Official research documentation states that data regarding the impact of long-term effects of Xiac are still emerging. This indicates that the long-term safety profile is not yet fully established across all studied populations, particularly for prolonged use.

Q: Why is Xiac not recommended for people with kidney disease?

A: While patients with kidney problems alone may not always require a dose change, official documents state that caution is advised, and the maximum daily dose should not exceed 2 grams for patients who have both severe renal (kidney) and hepatic (liver) impairment.

Q: Do I need to do blood tests while taking Xiac?

A: Official warnings note that Xiac can alter coagulation parameters, specifically mentioning a change in prothrombin time (a measure of how quickly blood clots). Regulatory documents advise that monitoring this may be necessary during treatment for patients with certain pre-existing conditions.

Q: Is Xiac a new drug or has it been around for a while?

A: Official regulatory assessments and historical reviews confirm that Xiac (ceftriaxone) is an established, well-studied agent. It has been in use as a powerful third-generation cephalosporin antibiotic for an extended period.

Q: Is it possible to have a side effect not listed in the official documents?

A: The official safety profile is continuously updated using information from clinical trials and post-marketing surveillance. Regulatory bodies advise that patients should report any suspected adverse reactions they experience, as this is the primary process used to identify and document new potential reactions.

Q: What should I do if my symptoms don't improve while taking Xiac?

A: Official patient information describes that you should contact a healthcare provider if your symptoms or health problems do not get better or if they become worse. This is important for determining whether the treatment plan needs adjustment.

Q: Does the time of day I take Xiac matter?

A: The official instructions indicate that Xiac is typically administered either once daily (every 24 hours) or in divided doses every 12 hours. There are no official instructions that specify a particular time of day (such as morning versus evening) for the administration.

Q: Can I crush or split Xiac tablets?

A: Xiac is not available in a pill or tablet form that can be crushed or split. It is supplied as a sterile powder that is intended to be reconstituted into a solution for injection or infusion by a healthcare professional.

Q: What should I do if I accidentally take too much Xiac?

A: Official patient instructions describe contacting a Poison Control Center or seeking emergency medical care if an overdose is suspected. Overdose can lead to increased side effects, and professional guidance is required right away.

Q: How often was Xiac studied in children?

A: Xiac has established use in various pediatric populations, including infants, children, and adolescents. Official guidelines detail specific weight-based dosing and indications for numerous infections, demonstrating that it has been studied extensively in this population.

Q: Are there different strengths of Xiac available?

A: Yes, Xiac is supplied as a sterile powder in different vial sizes for reconstitution. The official label lists common available sizes, typically including 250 mg, 500 mg, 1 g, 2 g, and 10 g powder vials.

How should Xiac be stored and disposed of?

The storage and disposal of Xiac (Ceftriaxone) must strictly adhere to the conditions outlined in its official regulatory labeling.

Storage Requirements

The un-reconstituted sterile powder must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) and kept protected from light in its original, tightly closed container. The solution prepared for injection has a limited shelf-life; it must be used immediately or stored under refrigeration (2 C to 8 C) for the period specified by the manufacturer, or for a shorter time at room temperature. It is a mandatory requirement to keep Xiac out of the sight and reach of children.

Handling and Disposal

Calcium-containing diluents must not be used for reconstitution. Disposal of any unused or expired product must be done as pharmaceutical waste and in compliance with federal, state, and local regulations. The preferred method is using a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Xiac found in:

A-Z Index: